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ABSTRACT
Wide variations in the types of pain and
response to analgesic pharmacotherapy mean
that a variety of treatment strategies are needed.
One approach is mesotherapy (intradermal
therapy). This consists of microinjections into
the skin and is ideally suited to the
management of localized pain. Advantages
include increasing the duration of drug
activity, reduced risk of adverse events and
interactions, and possible synergy with other
therapies. Mesotherapy provides general
practitioners with another tool for the
treatment of local pain. However, it is
important to provide patients with full details
of the pros and cons of this approach and




There is heterogeneity between different types
of pain due to different pathophysiological
mechanisms and response to analgesics [1, 2].
General practitioners (GPs) often detect
persistent localized pain in patients with
several coexisting disorders and who are at
high risk of adverse events. In these
circumstances, or when the use of pain
medication is contraindicated or cannot be
prescribed for long periods due to safety
reasons, the GP needs alternative therapeutic
strategies to control pain.
Mesotherapy (intradermal therapy) can be
included as an additional treatment approach
for the management of localized pain. It
consists of a series of micro-injections in the
upper layers of the skin. This allows a slow
diffusion of the drug compared with
deep-administration [3]. The micro-injections
are performed using a syringe with a 4-mm (27
gauge) needle or 13-mm (30 or 32 gauge)
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needle, usually inserted at an angle of about
30–45 with respect to the skin’s surface. This
technique has several advantages, including
modulation of drug kinetics with prolonged
local pharmacological activity, drug-sparing
effects, a reduction in the risk of systemic
interaction, and potential synergy with other
therapies [3]. Mesotherapy is applied for some
types of localized musculoskeletal pain and
clinical benefits have been shown with lower
doses of nonsteroidal anti-inflammatory drug
(NSAIDs), muscle relaxants, anesthetics, and
other analgesics. In fact, in a recent review [4]
it was observed that a series of open studies
involving a total of 2422 patients with various
types of pain (cervical pain, back pain,
tendinitis) highlighted a reduction in pain of
at least 50% from baseline. In addition to the
reduction of post-traumatic pain (778
professional athletes observed), a rapid
functional recovery was achieved after a
mesotherapy treatment.
The intradermal route of drug administration
has become an alternative to the intramuscular
route and is also being used for the
administration of vaccines due to a greater
immune response having been obtained with a
lower dose of antigen compared to the
intramuscular administration [5]. To practice
this technique the following are required:
clinical and pharmacological skills; ability to
select patients to be treated; and communication
skills to obtain valid informed consent. [6]. Over
the years, in many countries there has been a
growing interest in mesotherapy, especially in
the field of esthetic medicine, both to correct skin
disorders and to prevent the aging of the skin.
The strong appeal of cosmetic applications for
mesotherapy has resulted in use by non-medical
personnel with a variety of off-label medications.
Lack of compliance with minimum aseptic
requirements during cosmetic uses has
contributed to some adverse outcomes [7, 8].
Fortunately, recommendations for proper
medical use of this technique have been
suggested, particularly to manage patients with
minor localized pain syndrome [3, 4, 9]. In our
primary care setting, after querying a database
containing 2503 patients treated in the last 10
years (mean age 58.52 ? 12.13; age range 14–98;
58.01% female), we detected a significant
percentage of patients with one or more
contraindications for long-term systemic
anti-inflammatory drug treatment. In addition,
33.04% of the study population (827 patients
with an average age of 57 ± 1.52 years; 55.7%
male) had reported one or more episodes of
moderate or severe pain (of the hip, neck, back or
knee) secondary to osteo-articular disease. Of
those, 376 (45.5%) had a history of
cardiovascular disease, heart failure,
hypertension, renal impairment, diabetes
mellitus, gastrointestinal disorders, or chronic
obstructive pulmonary disease with asthma. A
total of 14.63% of patients with recurrent
episodes of localized pain (4.8% of the observed
population) aged 75 years and over had a history
of clinical and pharmacological conditions
suggesting that local treatment with
anti-inflammatory drugs would be more
appropriate than systemic. Based on available
data [4], we may assume that at least 50% of this
subgroup of patients (elderly, under multiple
treatments, and with more than one episode of
recurrent pain) could benefit from a local
treatment such as mesotherapy.
Although preliminary randomized
controlled trials conducted to date reported
clinical benefit in 332 patients with back pain,
cervicobrachialgia, and calcifying tendinitis of
the shoulder [10–14], we suggest more
well-designed randomized controlled studies
to better define the clinical role of
mesotherapy should be performed.
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Chronic musculoskeletal pain (including low
back, osteoarthritic, post-traumatic, and
neuropathic pain) results from a complex
interaction of mechanical and biochemical
factors. Frequently, many patients with this
type of localized pain cannot be treated with
long-term courses of NSAIDs due to safety
reasons, and in these cases, opioids are
suggested. However, these drugs should be
used carefully to prevent iatrogenic risk [15]. A
multimodal approach to pain may help to
reduce a drug’s toxicity by lowering the total
dose of any single drug used to target different
pain mechanisms. Under this point of view,
unmanageable localized pain could benefit
from a localized treatment that takes
advantage of the principles of mesotherapy
and may contribute to the reduction of the
systemic administration of medications.
CONCLUSION
In conclusion, GPs should consider local
analgesic strategies whenever systemic
treatment increases the risk of drug reactions
or interactions. In this setting, mesotherapy
may be a useful ally against unnecessary pain.
However, it should be underlined that any
analgesic technique has strengths and
weaknesses. Therefore, the patient should be
involved in pain management and informed
about potential risks and failures. For this
reason, informed consent is both good clinical
practice and helps the patient to fully
understand the limits and benefits of the
therapeutic strategy proposed [6].
Selecting patients and establishing a
treatment plan that takes advantage of the
drug-sparing effect of mesotherapy, alone or in
combination with other treatments, means the
patient may achieve therapeutic success. Of
course nothing is fixed, and the doctor has a
duty to consider carefully whether mesotherapy
is or is not appropriate in every individual case.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
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